Combination of Ribociclib with BET-Bromodomain and PI3K/mTOR Inhibitors for Medulloblastoma Treatment In Vitro and In Vivo

Abstract Despite improvement in the treatment of medulloblastoma over the last years, numerous patients with MYC- and MYCN-driven tumors still fail current therapies. Medulloblastomas have an intact retinoblastoma protein RB, suggesting that CDK4/6 inhibition might represent a therapeutic strategy for which drug combination remains understudied. We conducted high-throughput drug combination screens in a Group3 (G3) medulloblastoma line using the CDK4/6 inhibitor (CDK4/6i) ribociclib at IC20, referred to as an anchor, and 87 oncology drugs approved by FDA or in clinical trials. Bromodomain and extra terminal (BET) and PI3K/mTOR inhibitors potentiated ribociclib inhibition of proliferation in an established cell line and freshly dissociated tumor cells from intracranial xenografts of G3 and Sonic hedgehog (SHH) medulloblastomas in vitro. A reverse combination screen using the BET inhibitor JQ1 as anchor, revealed CDK4/6i as the most potentiating drugs. In vivo, ribociclib showed single-agent activity in medulloblastoma models whereas JQ1 failed to show efficacy due to high clearance and insufficient free brain concentration. Despite in vitro synergy, combination of ribociclib with the PI3K/mTOR inhibitor paxalisib did not significantly improve the survival of G3 and SHH medulloblastoma-bearing mice compared with ribociclib alone. Molecular analysis of ribociclib and paxalisib-treated tumors revealed that E2F targets and PI3K/AKT/MTORC1 signaling genes were depleted, as expected. Importantly, in one untreated G3MB model HD-MB03, the PI3K/AKT/MTORC1 gene set was enriched in vitro compared with in vivo suggesting that the pathway displayed increased activity in vitro. Our data illustrate the difficulty in translating in vitro findings in vivo. See related article in Mol Cancer Ther (2022) 21(8):1306–1317.

[1]  M. Roussel,et al.  Phenyl-Glutarimides: Alternative Cereblon Binders for the Design of PROTACs. , 2021, Angewandte Chemie.

[2]  X. Mu,et al.  Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor. , 2021, Cancer cell.

[3]  Nathaniel R. Twarog,et al.  Patient-derived models recapitulate heterogeneity of molecular signatures and drug response in pediatric high-grade glioma , 2021, Nature Communications.

[4]  H. Rugo,et al.  The evolution of cyclin dependent kinase inhibitors in the treatment of cancer , 2021, Expert review of anticancer therapy.

[5]  E. Tirrò,et al.  PI3K INHIBITION IN BREAST CANCER: IDENTIFYING AND OVERCOMING DIFFERENT FLAVORS OF RESISTANCE. , 2021, Critical reviews in oncology/hematology.

[6]  Steven J. M. Jones,et al.  The transcriptional landscape of Shh medulloblastoma , 2021, Nature Communications.

[7]  M. Roussel,et al.  Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastoma , 2021, Science Translational Medicine.

[8]  Zhenbo Hu,et al.  Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitors for the Treatment of Hematological Malignancies and Solid Tumors: A Systematic Study of Clinical Trials , 2021, Frontiers in Pharmacology.

[9]  Jessica M. Rusert,et al.  Functional Precision Medicine Identifies New Therapeutic Candidates for Medulloblastoma , 2020, Cancer Research.

[10]  G. Sartor,et al.  BET bromodomains as novel epigenetic targets for brain health and disease , 2020, Neuropharmacology.

[11]  D. Slamon,et al.  Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer , 2020, Breast Cancer Research.

[12]  M. Roussel,et al.  Patient-derived orthotopic xenografts of pediatric brain tumors: a St. Jude resource , 2020, Acta Neuropathologica.

[13]  L. Pusztai,et al.  Overall survival of CDK4/6-inhibitors-based treatments in clinically relevant subgroups of metastatic breast cancer: systematic review and meta-analysis. , 2020, Journal of the National Cancer Institute.

[14]  Dailin Liang,et al.  Novel strategies targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery. , 2020, European journal of medicinal chemistry.

[15]  Thomas O. McDonald,et al.  Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer , 2020, Nature Communications.

[16]  M. Malumbres,et al.  Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition. , 2020, Cancer cell.

[17]  Eric W Prince,et al.  Targeting MYC-driven replication stress in medulloblastoma with AZD1775 and gemcitabine , 2020, Journal of Neuro-Oncology.

[18]  R. Bianco,et al.  Mechanisms of resistance to mTOR inhibitors. , 2020, Critical reviews in oncology/hematology.

[19]  Paul A. Northcott,et al.  scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy , 2019, Nature Communications.

[20]  Z. Rankovic,et al.  Practical approaches to evaluating and optimizing brain exposure in early drug discovery. , 2019, European journal of medicinal chemistry.

[21]  Qiaojun He,et al.  Molecular basis for class side effects associated with PI3K/AKT/mTOR pathway inhibitors , 2019, Expert opinion on drug metabolism & toxicology.

[22]  M. Kool,et al.  Subgroup-specific prognostic signaling and metabolic pathways in pediatric medulloblastoma , 2019, BMC Cancer.

[23]  Emily J. Girard,et al.  Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma , 2019, Nature Communications.

[24]  S. Baker,et al.  CNS penetration of the CDK4/6 inhibitor ribociclib in non-tumor bearing mice and mice bearing pediatric brain tumors , 2019, Cancer Chemotherapy and Pharmacology.

[25]  M. Roussel,et al.  Preclinical Modeling of Image-Guided Craniospinal Irradiation for Very-High-Risk Medulloblastoma. , 2019, International journal of radiation oncology, biology, physics.

[26]  Marcus Schmidt,et al.  Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer , 2018, Therapeutic advances in medical oncology.

[27]  S. Elledge,et al.  Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4/6is , 2018, Genes & development.

[28]  T. Curran.  Reproducibility of academic preclinical translational research: lessons from the development of Hedgehog pathway inhibitors to treat cancer , 2018, Open Biology.

[29]  J. Qi,et al.  Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma , 2016, Oncogene.

[30]  S. Loi,et al.  Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer. , 2017, Cancer research.

[31]  M. Cascante,et al.  De novo MYC addiction as an adaptive response of cancer cells to CDK4/6 inhibition , 2017, Molecular systems biology.

[32]  Sirintra Nakjang,et al.  Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study , 2017, The Lancet. Oncology.

[33]  Melissa J. Davis,et al.  Inhibition of CDK4/6 by Palbociclib Significantly Extends Survival in Medulloblastoma Patient-Derived Xenograft Mouse Models , 2017, Clinical Cancer Research.

[34]  B. Coyle,et al.  In vitro models of medulloblastoma: Choosing the right tool for the job. , 2016, Journal of biotechnology.

[35]  G. Shapiro,et al.  A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas , 2016, Clinical Cancer Research.

[36]  Elizabeth Stewart,et al.  BRAID: A Unifying Paradigm for the Analysis of Combined Drug Action , 2016, Scientific Reports.

[37]  G. Shapiro,et al.  Targeting CDK4 and CDK6: From Discovery to Therapy. , 2016, Cancer discovery.

[38]  J. Olson,et al.  HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma. , 2016, Cancer cell.

[39]  J. Mesirov,et al.  DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets , 2016, Clinical Cancer Research.

[40]  S. Sideris,et al.  Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR , 2016, ACS medicinal chemistry letters.

[41]  M. Roussel,et al.  Preclinical studies of 5-fluoro-2′-deoxycytidine and tetrahydrouridine in pediatric brain tumors , 2015, Journal of Neuro-Oncology.

[42]  Florence I. Raynaud,et al.  Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease , 2015, Cancer cell.

[43]  R. Beroukhim,et al.  Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition , 2014, Nature Medicine.

[44]  J. Olson,et al.  Pemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastoma. , 2014, Cancer cell.

[45]  R. Beroukhim,et al.  BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma , 2013, Clinical Cancer Research.

[46]  F. Speleman,et al.  BET bromodomain protein inhibition is a therapeutic option for medulloblastoma , 2013, Oncotarget.

[47]  Stefan M. Pfister,et al.  HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment , 2012, Journal of Neuro-Oncology.

[48]  Steven J. M. Jones,et al.  Subgroup-specific structural variation across 1,000 medulloblastoma genomes , 2012, Nature.

[49]  P. Sandy,et al.  Targeting MYC dependence in cancer by inhibiting BET bromodomains , 2011, Proceedings of the National Academy of Sciences.

[50]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[51]  D. Waxman,et al.  Sex Differences in the Expression of Hepatic Drug Metabolizing Enzymes , 2009, Molecular Pharmacology.

[52]  R Czerniak,et al.  Gender-Based Differences in Pharmacokinetics in Laboratory Animal Models , 2001, International journal of toxicology.